8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Vertex reports 12% revenue growth and raises 2026 guidance
Filed with the SEC on · Summarized by InvestorsBot
Vertex reported third-quarter 2026 revenue of $3.44 billion, up 12% from a year earlier, while GAAP net income fell to $654 million from $1.08 billion because of Crinetics Pharmaceuticals acquisition costs; non-GAAP net income was $1.21 billion. The company raised full-year 2026 revenue guidance to $13.15 billion-$13.25 billion, completed its approximately $10 billion Crinetics acquisition on September 1, and expects an FDA decision on povetacicept for IgA nephropathy by November 30.